# Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults

> **NCT03316807** · PHASE4 · COMPLETED · sponsor: **Suping Wang** · enrollment: 182 (actual)

## Conditions studied

- Hepatitis B Vaccine

## Interventions

- **BIOLOGICAL:** 60 µg dose hepatitis B vaccine
- **BIOLOGICAL:** 20 µg dose hepatitis B vaccine

## Key facts

- **NCT ID:** NCT03316807
- **Lead sponsor:** Suping Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-07
- **Final completion:** 2018-07
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316807, "Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03316807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*